UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~May~~June 2925, 2024

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

001-37769

N/A

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

160 Second Street, Floor 3

Cambridge, Massachusetts

02142

(Address of principal executive offices)

(Zip Code)

(617) 830-3031

(Registrant’s telephone number, including area code)

N/A

(Former Name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4©(c) under the Exchange Act (17 CFR 240.13e-4©(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of ~~each~~ exchange on which registered Common Shares, no par value per share VBIV The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0107 ~~Regulation~~Submission FDof ~~Disclosure~~Matters to a Vote of Security Holders.

On ~~May~~June 2925, 2024, VBI Vaccines Inc. (the “Company”) ~~issued~~held aits ~~press~~2024 ~~release~~Annual ~~announcing~~General ~~new~~Meeting ~~interim~~of ~~tumor~~Shareholders ~~response~~(the ~~data~~“Annual Meeting”). ~~from~~At the ~~ongoing~~ ~~randomized~~Annual Meeting, ~~controlled~~the ~~Phase~~shareholders 2bvoted ~~study~~to: (1) elect the nominated directors of ~~VBI-1901,~~the Company to serve until the next annual meeting of shareholders or until the appointment or election and qualification of their successors and (2) approve the appointment of EisnerAmper LLP as the Company’s ~~immunotherapeutic~~independent ~~cancer~~registered ~~vaccine~~public ~~candidate,~~accounting infirm ~~recurrent~~until the next annual meeting of shareholders ~~glioblastoma~~and to authorize the audit committee (~~rGBM~~the “Audit Committee”) ~~patients.~~of ~~The~~the ~~Company~~board ~~undertakes~~of nodirectors ~~obligation~~of the Company to ~~update~~fix EisnerAmper LLP’s remuneration, ~~supplement~~as orset ~~amend~~forth in the ~~materials~~Company’s ~~attached~~definitive ~~hereto~~proxy statement filed with the U.S. Securities and Exchange Commission on April 29, 2024 (the “Proxy Statement”). Each of these proposals is described in more detail in the Proxy Statement.

~~The~~At ~~information~~the inbeginning ~~this~~of ~~Current~~the ~~Report~~Annual onMeeting, ~~Form~~there ~~8-K~~were ~~(including~~13,879,327 ~~Exhibit~~common ~~99.1~~shares ~~attached~~present ~~hereto)~~at isthe ~~being~~Annual ~~furnished~~Meeting ~~pursuant~~in toperson ~~Item~~or ~~7.01~~by ~~and~~proxy, ~~shall~~which ~~not~~represented be48.39% ~~deemed~~of tothe beoutstanding ~~filed~~common ~~for~~shares ~~purposes~~entitled ofto ~~Section~~vote 18at of the ~~Securities~~Annual ~~Exchange~~Meeting ~~Act~~and ofwhich ~~1934,~~constituted asa ~~amended~~quorum for (the ~~“Exchange~~transaction ~~Act”), or~~of ~~otherwise~~business. beHolders ~~subject~~of to the ~~liabilities~~Company’s ofcommon ~~that~~shares ~~section,~~were ~~nor~~entitled ~~shall it be deemed~~ to beone ~~incorporated~~vote byfor ~~reference~~each inshare ~~any~~held ~~filing~~as ~~under~~ of the close ~~Securities~~of ~~Act~~business ofon ~~1933~~April 26, ~~as amended~~2024, or the ~~Exchange~~record ~~Act,~~date ~~whether~~for ~~made before or after~~ the ~~date~~Annual ~~hereof and regardless of any general incorporation language in such filing~~Meeting.

The voting results on these proposals were as follows:

Proposal 1: Election of eight directors

Director	Votes For		Withheld		Broker Non-Votes
Steven Gillis		3,663,424		882,856		9,333,047
Damian Braga		3,651,602		892,907		9,334,818
Joanne Cordeiro		3,776,579		769,703		9,333,045
Michel De Wilde		3,625,156		919,353		9,334,818
Vaughn Himes		3,813,210		733,071		9,333,046
Blaine H. McKee		3,778,849		767,432		9,333,046
Jeffrey R. Baxter		3,685,583		858,927		9,334,817
Nell Beattie		3,714,249		830,260		9,334,818

Each of the eight nominees for director was elected to serve until the next annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal.

Proposal 2: Approval of the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company until the next annual meeting of shareholders and to authorize the Audit Committee to fix EisnerAmper LLP’s remuneration

Votes For		Votes Against				Abstentions				Broker Non-Votes
12,931,798			0				947,529				0

The shareholders approved the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm until the next annual meeting of shareholders and authorized the Audit Committee to fix EisnerAmper LLP’s remuneration.

Item 8.01 Other Events.

On June 25, 2024, the Company issued a press release announcing the voting results from the Annual Meeting. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated ~~May~~June 2925, 2024 ~~(furnished pursuant to Item 7.01)~~
104		Cover Page Interactive Data File (~~formatted~~embedded aswithin the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VBI Vaccines Inc.
Date: May 29, 2024	By:	/s/ Jeffrey R. Baxter
Date: June 25, 2024	By:	/s/ Jeffrey R. Baxter
		Jeffrey R. Baxter
		President and Chief Executive Officer

Filing Compare · VBI Vaccines Inc/BC